Drug Trial Radar · NCT07502638
FXS6837 for the Treatment of IgAN Patients
Last checked: Nov 19, 2026Latest source record: Mar 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Mar 31, 2026
Primary completion
Sep 12, 2027
Study completion Nov 14, 2027
Sponsor
- Lead sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 31, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo controlled Phase IIb study to explore the efficacy and safety of FXS6837 capsules in IgAN patients. About 60 patients dignosed with primary IgAN will be enrolled and randomized to three cohorts and take different dosage of FXS6837 or placebo capsules orally according to protocol.
Conditions
- IgAN
Interventions
FXS6837 Dose 1Drug
FXS6837 taken orally once a day
FXS6837 Dose 2Drug
FXS6837 taken orally once a day
Placebo CapsuleDrug
Placebo taken orally once a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ratio to baseline in Urine Protein to Creatinine Ratio (sampled from 24h urine collection) at Day180Time frame: baseline and Day180
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.